October 13, 2022
GSK’s Older Adult Respiratory Syncytial Virus (RSV) Vaccine Candidate Shows 94.1% Reduction in Severe RSV Disease and Overall Vaccine Efficacy of 82.6% in Pivotal Trial
August 16, 2022
GSK Completes Acquisition of Affinivax, Inc.
July 15, 2022
GSK Welcomes Agreement with the Government of Canada for the Provision of Pandemic and Seasonal Influenza Vaccines
No current content.